gut health

Akkermansia Gut Health Randomized Trial Evidence Table

Structured evidence table for Akkermansia Gut Health Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.

topicclaimevidence levelcitationsource
Akkermansia Gut Health Randomized TrialYounossi et al., 2016 Younossi et al., 2025 Tilg et al., 2022 Hsu and Schnabl, 2023 Liu et al., 2026 Depommier et al., 2019 Wu et al., 2020a Akkermansia muciniphila Metabolic dysfunction-associated steatotic liver disease (MASLD) affects about one-third of adults and is sustained by interacting metabolic, inflammatory, and microbial processes (;).3Liu Yifan (2026)Pasteurized Akkermansia muciniphila as a candidate multi-effector pharmacological system in the gut-liver axis: evidence, unresolved causality, and translational priorities
Akkermansia Gut Health Randomized TrialRecords were eligible if they reportedpreparations (live, pasteurized, or component-defined) or-associated effectors (proteins, extracellular vesicles, lipids, or metabolites) in metabolic or liver-relevant models or in human studies.3Liu Yifan (2026)Pasteurized Akkermansia muciniphila as a candidate multi-effector pharmacological system in the gut-liver axis: evidence, unresolved causality, and translational priorities
Akkermansia Gut Health Randomized Trialmuciniphila ClinicalTrials.gov Representative evidence linking pasteurizedand its effectors to metabolic and liver-relevant outcomes.3Liu Yifan (2026)Pasteurized Akkermansia muciniphila as a candidate multi-effector pharmacological system in the gut-liver axis: evidence, unresolved causality, and translational priorities
Akkermansia Gut Health Randomized TrialThe gut-liver axis links intestinal barrier integrity, microbial products, and hepatic immune-metabolic responses, making microbial therapeutics attractive but pharmacologically hard to define (;).is prominent here because live, pasteurized, and component-based preparations each produce metabolic or liver-relevant effects, and pasteurized whole cells have already entered human studies (;;).3Liu Yifan (2026)Pasteurized Akkermansia muciniphila as a candidate multi-effector pharmacological system in the gut-liver axis: evidence, unresolved causality, and translational priorities
Akkermansia Gut Health Randomized TrialAging is often associated with intestinal microbiota imbalance and immune system degeneration.4Xia T (2026)Associations Between Gut Microbiota and Immune Profiles in Community-Dwelling Older Adults and the Regulatory Role of Polygonatum odoratum.
Akkermansia Gut Health Randomized TrialBaseline correlation analysis revealed that alterations in gut microbiota were predominantly associated with T cell subsets.4Xia T (2026)Associations Between Gut Microbiota and Immune Profiles in Community-Dwelling Older Adults and the Regulatory Role of Polygonatum odoratum.
Akkermansia Gut Health Randomized TrialAfter 90-day YZG intervention, the percentage of TEMRA and CD28 - CD57 + TEMRA cells were reduced in elderly subjects.4Xia T (2026)Associations Between Gut Microbiota and Immune Profiles in Community-Dwelling Older Adults and the Regulatory Role of Polygonatum odoratum.
Akkermansia Gut Health Randomized TrialThe dysregulation and crosstalk of these two factors markedly elevate the elderly's susceptibility to infections and age-related diseases.4Xia T (2026)Associations Between Gut Microbiota and Immune Profiles in Community-Dwelling Older Adults and the Regulatory Role of Polygonatum odoratum.
topicAkkermansia Gut Health Randomized Trial
claimYounossi et al., 2016 Younossi et al., 2025 Tilg et al., 2022 Hsu and Schnabl, 2023 Liu et al., 2026 Depommier et al., 2019 Wu et al., 2020a Akkermansia muciniphila Metabolic dysfunction-associated steatotic liver disease (MASLD) affects about one-third of adults and is sustained by interacting metabolic, inflammatory, and microbial processes (;).
evidence level3
citationLiu Yifan (2026)
sourcePasteurized Akkermansia muciniphila as a candidate multi-effector pharmacological system in the gut-liver axis: evidence, unresolved causality, and translational priorities
topicAkkermansia Gut Health Randomized Trial
claimRecords were eligible if they reportedpreparations (live, pasteurized, or component-defined) or-associated effectors (proteins, extracellular vesicles, lipids, or metabolites) in metabolic or liver-relevant models or in human studies.
evidence level3
citationLiu Yifan (2026)
sourcePasteurized Akkermansia muciniphila as a candidate multi-effector pharmacological system in the gut-liver axis: evidence, unresolved causality, and translational priorities
topicAkkermansia Gut Health Randomized Trial
claimmuciniphila ClinicalTrials.gov Representative evidence linking pasteurizedand its effectors to metabolic and liver-relevant outcomes.
evidence level3
citationLiu Yifan (2026)
sourcePasteurized Akkermansia muciniphila as a candidate multi-effector pharmacological system in the gut-liver axis: evidence, unresolved causality, and translational priorities
topicAkkermansia Gut Health Randomized Trial
claimThe gut-liver axis links intestinal barrier integrity, microbial products, and hepatic immune-metabolic responses, making microbial therapeutics attractive but pharmacologically hard to define (;).is prominent here because live, pasteurized, and component-based preparations each produce metabolic or liver-relevant effects, and pasteurized whole cells have already entered human studies (;;).
evidence level3
citationLiu Yifan (2026)
sourcePasteurized Akkermansia muciniphila as a candidate multi-effector pharmacological system in the gut-liver axis: evidence, unresolved causality, and translational priorities
topicAkkermansia Gut Health Randomized Trial
claimAging is often associated with intestinal microbiota imbalance and immune system degeneration.
evidence level4
citationXia T (2026)
sourceAssociations Between Gut Microbiota and Immune Profiles in Community-Dwelling Older Adults and the Regulatory Role of Polygonatum odoratum.
topicAkkermansia Gut Health Randomized Trial
claimBaseline correlation analysis revealed that alterations in gut microbiota were predominantly associated with T cell subsets.
evidence level4
citationXia T (2026)
sourceAssociations Between Gut Microbiota and Immune Profiles in Community-Dwelling Older Adults and the Regulatory Role of Polygonatum odoratum.
topicAkkermansia Gut Health Randomized Trial
claimAfter 90-day YZG intervention, the percentage of TEMRA and CD28 - CD57 + TEMRA cells were reduced in elderly subjects.
evidence level4
citationXia T (2026)
sourceAssociations Between Gut Microbiota and Immune Profiles in Community-Dwelling Older Adults and the Regulatory Role of Polygonatum odoratum.
topicAkkermansia Gut Health Randomized Trial
claimThe dysregulation and crosstalk of these two factors markedly elevate the elderly's susceptibility to infections and age-related diseases.
evidence level4
citationXia T (2026)
sourceAssociations Between Gut Microbiota and Immune Profiles in Community-Dwelling Older Adults and the Regulatory Role of Polygonatum odoratum.

Learn next

Related evidence and supplement guides

GuideGut Health Supplement Stack: Probiotics, Prebiotics & GlutamineLegacy library material — check the original sources.Guide女性必知：Magnesium Glycinate如何缓解PMS和更年期症状Legacy library material — check the original sources.GuideLion's Mane Mushroom: What the Evidence Actually Shows for Brain HealthLegacy library material — check the original sources.GuideWhat is Magnesium GlycinateLegacy library material — check the original sources.AnswerDoes Prebiotic Xylooligosaccharides Gut Health Randomized Trial work?Legacy library material — check the original sources.AnswerIs Prebiotic Xylooligosaccharides Gut Health Randomized Trial safe?Legacy library material — check the original sources.AnswerWhat does the evidence say about Prebiotic Xylooligosaccharides Gut Health Randomized Trial?Legacy library material — check the original sources.AnswerDoes Pectin Gut Health Randomized Trial work?Legacy library material — check the original sources.

Source documents

  1. Pasteurized Akkermansia muciniphila as a candidate multi-effector pharmacological system in the gut-liver axis: evidence, unresolved causality, and translational priorities
  2. Associations Between Gut Microbiota and Immune Profiles in Community-Dwelling Older Adults and the Regulatory Role of Polygonatum odoratum.